Lamivudine
- Generic Name
- Lamivudine
- Brand Names
- Cimduo, Combivir, Delstrigo, Dovato, Epivir, Epivir Hbv, Epzicom, Kivexa, Symfi, Triumeq, Trizivir, Zeffix, Lamivudine Teva Pharma B.V., Lamivudine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C8H11N3O3S
- CAS Number
- 134678-17-4
- Unique Ingredient Identifier
- 2T8Q726O95
- Background
A reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV).
- Indication
For the treatment of HIV infection and chronic hepatitis B (HBV).
- Associated Conditions
- Chronic Hepatitis B Infection, Human Immunodeficiency Virus (HIV) Infections, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
Antiretroviral Regime for Viral Eradication in Newborns
- Conditions
- Interventions
- First Posted Date
- 2016-03-18
- Last Posted Date
- 2022-09-28
- Target Recruit Count
- 600
- Registration Number
- NCT02712801
- Locations
- 🇨🇳
Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China
🇨🇳Maternal and Child Health Hospital of Guangdong Province, Guangzhou, Guangdong, China
🇨🇳Maternal and Child Health Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China
Simplification From Tenofovir Plus Lamivudine or Emtricitabine Plus Ritonavir-Boosted-Protease Inhibitor to Ritonavir-Boosted-Atazanavir Plus Lamivudine in Virologically-Suppressed-HIVInfected Adults With Osteopenia
- Conditions
- Interventions
- First Posted Date
- 2016-01-12
- Last Posted Date
- 2016-08-17
- Lead Sponsor
- David Garcia Cinca
- Target Recruit Count
- 45
- Registration Number
- NCT02652793
- Locations
- 🇪🇸
Hospital Clínic i Provincial de Barcelona, Barcelona, Spain
A Phase IV, Open Label, 4-period Cross-over Study to Investigate a Drug Interaction Between Lamivudine and Sorbitol Oral Solutions in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2015-12-17
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 16
- Registration Number
- NCT02634073
- Locations
- 🇺🇸
GSK Investigational Site, Overland Park, Kansas, United States
Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years
- Conditions
- Interventions
- First Posted Date
- 2015-11-30
- Last Posted Date
- 2020-03-04
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 167
- Registration Number
- NCT02616783
- Locations
- 🇫🇷
Hopital Necker les Enfants Malades, Paris, France
🇧🇪University Hospital Gent, Ghent, Belgium
🇮🇹Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy
A Study to Evaluate Efficacy and Safety of Peginterferon Alfa-2a (Pegasys) and Adeforvir Dipivoxil (ADV) in Participants With Lamivudine-Resistant Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B
- Conditions
- Interventions
- First Posted Date
- 2015-11-05
- Last Posted Date
- 2016-02-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 255
- Registration Number
- NCT02598063
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
- First Posted Date
- 2015-10-21
- Last Posted Date
- 2018-05-09
- Target Recruit Count
- 122
- Registration Number
- NCT02582684
- Locations
- 🇺🇸
University of Southern California CRS (1201), Los Angeles, California, United States
🇺🇸UCLA CARE Center CRS (601), Los Angeles, California, United States
🇺🇸Harbor-UCLA Med. Ctr. CRS (603), Torrance, California, United States
The Effectiveness of Dual Therapy (Lopinavir/Ritonavir + LamivudinE) in Treatment-Experienced HIV Infected Patients in the Russian Federation
- First Posted Date
- 2015-10-20
- Last Posted Date
- 2019-06-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 216
- Registration Number
- NCT02581202
Pharmacokinetics of Atazanavir /Dolutegravir/Lamivudine Regimen as Maintenance Regimen
- Conditions
- Interventions
- First Posted Date
- 2015-10-02
- Last Posted Date
- 2020-12-07
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 9
- Registration Number
- NCT02566707
- Locations
- 🇳🇱
St. Elisabeth, Tilburg, Netherlands
🇳🇱Rijstate, Arnhem, Netherlands
🇳🇱Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
An Exploratory Study of RGT Strategy on Optimal NUC-experienced Patients
- First Posted Date
- 2015-09-25
- Last Posted Date
- 2015-09-25
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 324
- Registration Number
- NCT02560649
Compare Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With LAM-resistant Chronic Hepatitis B
- First Posted Date
- 2015-06-26
- Last Posted Date
- 2015-12-30
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 90
- Registration Number
- NCT02482272
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.